TNGX

Company Overview — What Does Tango Therapeutics, Inc. Do?

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts. Tango Therapeutics, Inc. (TNGX) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Barbara L. Weber and employs approximately 90 people. With a market capitalization of $3.0B, TNGX is one of the notable companies in the Healthcare sector.

Tango Therapeutics, Inc. (TNGX) Stock Rating — Hold (April 2026)

As of April 2026, Tango Therapeutics, Inc. receives a Hold rating with a composite score of 36.5/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.TNGX ranks #1,871 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Tango Therapeutics, Inc. ranks #193 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TNGX Stock Price and 52-Week Range

Tango Therapeutics, Inc. (TNGX) currently trades at $19.95. The stock lost $0.75 (3.6%) in the most recent trading session. The 52-week high for TNGX is $18.97, which means the stock is currently trading 5.2% from its annual peak. The 52-week low is $1.03, putting the stock 1836.9% above its annual trough. Recent trading volume was 1.7M shares, reflecting moderate market activity.

Is TNGX Overvalued or Undervalued? — Valuation Analysis

Tango Therapeutics, Inc. (TNGX) carries a value factor score of 30/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 122.50x, compared to the Healthcare sector average of 23.63x — a premium of 418%. The price-to-book ratio stands at 8.16x, versus the sector average of 2.75x. The price-to-sales ratio is 38.18x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, TNGX trades at 43.07x EV/EBITDA, versus 6.34x for the sector.

At current multiples, Tango Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Tango Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Tango Therapeutics, Inc. (TNGX) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -26.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -23.1% versus the sector average of -33.1%.

On a margin basis, Tango Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -583.4% (sector: -66.1%). Net profit margin stands at -545.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 170.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TNGX Debt, Balance Sheet, and Financial Health

Tango Therapeutics, Inc. has a debt-to-equity ratio of 15.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 16.32x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $58M.

TNGX has a beta of 1.14, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Tango Therapeutics, Inc. is 21/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Tango Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Tango Therapeutics, Inc. reported revenue of $74M and earnings per share (EPS) of $-0.87. Net income for the quarter was $-92M. Gross margin was 100.0%. Operating income came in at $-102M.

In FY 2025, Tango Therapeutics, Inc. reported revenue of $62M and earnings per share (EPS) of $-0.87. Net income for the quarter was $-102M. Revenue grew 48.3% year-over-year compared to FY 2024. Operating income came in at $-111M.

In Q3 2025, Tango Therapeutics, Inc. reported revenue of $54M and earnings per share (EPS) of $0.14. Net income for the quarter was $16M. Revenue grew 363.6% year-over-year compared to Q3 2024. Operating income came in at $14M.

In Q2 2025, Tango Therapeutics, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.35. Net income for the quarter was $-39M. Revenue grew -84.0% year-over-year compared to Q2 2024. Operating income came in at $-41M.

Over the past 8 quarters, Tango Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $20M to $74M. Investors analyzing TNGX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TNGX Dividend Yield and Income Analysis

Tango Therapeutics, Inc. (TNGX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TNGX Momentum and Technical Analysis Profile

Tango Therapeutics, Inc. (TNGX) has a momentum factor score of 80/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 4/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

TNGX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Tango Therapeutics, Inc. (TNGX) ranks #193 out of 838 stocks based on the Blank Capital composite score. This places TNGX in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TNGX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TNGX vs S&P 500 (SPY) comparison to assess how Tango Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

TNGX Next Earnings Date

No upcoming earnings date has been announced for Tango Therapeutics, Inc. (TNGX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TNGX? — Investment Thesis Summary

Tango Therapeutics, Inc. presents a balanced picture with arguments on both sides. The quality score of 25/100 flags below-average profitability. The value score of 30/100 indicates premium valuation. Price momentum is positive at 80/100, suggesting the trend favors buyers. High volatility (stability score 21/100) increases portfolio risk.

In summary, Tango Therapeutics, Inc. (TNGX) earns a Hold rating with a composite score of 36.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TNGX stock.

Related Resources for TNGX Investors

Explore more research and tools: TNGX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TNGX head-to-head with peers: TNGX vs AZN, TNGX vs SLGL, TNGX vs VMD.